<DOC>
	<DOCNO>NCT00471159</DOCNO>
	<brief_summary>To assess efficacy safety PF-3512676 administer combination docetaxel treatment patient advance breast cancer .</brief_summary>
	<brief_title>A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Female patient confirm advanced breast cancer . Patients HER2 negative disease document disease progression ( neo ) adjuvant treatment anthracyclinebased chemotherapy regimen . Patients adequate general wellbeing , kidney liver function . Patients condition could affect patient safety , interfere trial result , make patient inappropriate inclusion study . Patients prior chemotherapy advance breast cancer . Patients childbearing potential unwilling use contraception .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>